COMMENTARY

Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key

October 13, 2015
A basic plan for so-called “humanitarian trials,” or a Japanese version of the compassionate use system, was announced in September. The plan would permit expanded access to new drugs following domestic “main studies,” or during such studies (after patient enrollment…

To read the full story

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Takashi Ebisawa

On January 8, Japan’s biggest-ever outbound acquisition is expected to come to fruition, with London-listed Shire coming under the wing of Takeda Pharmaceutical. The Japanese major is paying £46 billion, or about 7 trillion yen, for the cash-and-stock deal, and…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…